IN2014DN03247A - - Google Patents

Info

Publication number
IN2014DN03247A
IN2014DN03247A IN3247DEN2014A IN2014DN03247A IN 2014DN03247 A IN2014DN03247 A IN 2014DN03247A IN 3247DEN2014 A IN3247DEN2014 A IN 3247DEN2014A IN 2014DN03247 A IN2014DN03247 A IN 2014DN03247A
Authority
IN
India
Prior art keywords
progestin
estrogen
disclosed
composition
transdermal delivery
Prior art date
Application number
Inventor
Charles G Arnold
Agis Kydonieus
Thomas M Rossi
Alfred F Altomari
Original Assignee
Agile Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agile Therapeutics Inc filed Critical Agile Therapeutics Inc
Publication of IN2014DN03247A publication Critical patent/IN2014DN03247A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates

Abstract

A composition for transdermal delivery of a progestin for progestin hormone therapy is disclosed. Also disclosed is a transdermal delivery device comprising the composition. For progestin only hormone therapy the composition contains an anti oxidant and does not contain an estrogen. For therapy involving a progestin and an estrogen the composition contains the progestin the estrogen and an additional anti oxidant. Methods of improving the stability of progestin containing compositions comprising oxidative agents are also disclosed. The methods comprise including one or more anti oxidants in the compositions.
IN3247DEN2014 2011-11-04 2012-11-02 IN2014DN03247A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555546P 2011-11-04 2011-11-04
US201261645778P 2012-05-11 2012-05-11
PCT/US2012/063314 WO2013067346A1 (en) 2011-11-04 2012-11-02 Dermal delivery compositions and methods

Publications (1)

Publication Number Publication Date
IN2014DN03247A true IN2014DN03247A (en) 2015-05-22

Family

ID=47278507

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3247DEN2014 IN2014DN03247A (en) 2011-11-04 2012-11-02

Country Status (16)

Country Link
US (3) US9364487B2 (en)
EP (1) EP2773333B1 (en)
JP (1) JP6316749B2 (en)
KR (1) KR20140088199A (en)
CN (1) CN103957899A (en)
AU (1) AU2012332254B2 (en)
BR (1) BR112014010670A2 (en)
CA (1) CA2854164C (en)
EA (1) EA026664B1 (en)
ES (1) ES2762460T3 (en)
HK (2) HK1200317A1 (en)
IL (1) IL232258A0 (en)
IN (1) IN2014DN03247A (en)
MX (1) MX353713B (en)
WO (1) WO2013067346A1 (en)
ZA (1) ZA201402988B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6285866B2 (en) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． Natural complex hormone replacement preparations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
GB2521632B (en) * 2013-12-23 2020-12-16 Linscott Goode Steven Vermin control compositions
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017059070A1 (en) 2015-09-29 2017-04-06 Amag Pharmaceuticals, Inc. Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (en) 2016-04-01 2019-01-29 Therapeuticsmd Inc pharmaceutical composition of steroid hormone
TW201922260A (en) * 2017-10-30 2019-06-16 日商帝國製藥股份有限公司 Formulation for transdermal administration
AU2018358372A1 (en) * 2017-10-30 2020-05-28 Kaken Pharmaceutical Co., Ltd. External preparation for treating trichophytosis unguium
BR112021005253A2 (en) 2018-09-19 2021-06-15 Isp Investments Llc peroxide stable polymer composition and process for its preparation and applications
CN113455506A (en) * 2021-06-29 2021-10-01 无锡宏霸医疗科技有限公司 Water-phase deodorizing agent suitable for daily chemical products and preparation method thereof
CN114259498B (en) * 2021-12-02 2023-04-28 南通联亚药业股份有限公司 Pharmaceutical composition containing desogestrel and ethinyl estradiol as well as preparation method and application thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
FR2739031B1 (en) * 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique TRANSDERMAL MATRIX SYSTEM FOR ADMINISTRATION OF AN ESTROGEN AND / OR A PROGESTIVE BASED ON STYRENE-ISOPRENE-STYRENE COPOLYMER, PREPARATION METHOD AND THERAPEUTIC USE
DE19700913C2 (en) * 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermal therapeutic system for the delivery of hormones
IT1294748B1 (en) * 1997-09-17 1999-04-12 Permatec Tech Ag FORMULATION FOR A TRANSDERMAL DEVICE
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
WO2001001990A1 (en) * 1999-07-01 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Adhesive preparation for percutaneous absorption
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
CA2391430C (en) * 1999-11-24 2009-10-06 Agile Therapeutics, Inc. Improved transdermal contraceptive delivery system and process
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
EP1127567B1 (en) * 2000-02-17 2010-09-01 Basf Se Aqueous dispersions of water insoluble organic sunscreens
JP4422430B2 (en) * 2003-05-14 2010-02-24 帝國製薬株式会社 External patch containing estrogen and / or progestogen
WO2006036899A2 (en) * 2004-09-27 2006-04-06 Corium International, Inc. Transdermal systems for the delivery of estrogens and progestins
CA2604943C (en) * 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
AU2006249349B2 (en) * 2005-05-26 2012-01-12 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
DE102006050558B4 (en) * 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing norelgestromin for contraception and hormone replacement
US20080175905A1 (en) * 2006-11-29 2008-07-24 Wyeth Estrogen/serm and estrogen/progestin bi-layer tablets
WO2009009651A1 (en) 2007-07-10 2009-01-15 Agile Therapeutics, Inc. Dermal delivery device with ultrasonic weld
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
US8246978B2 (en) 2007-07-10 2012-08-21 Agile Therapeutics, Inc. Dermal delivery device with reduced loss of its volatile components
WO2009142699A1 (en) * 2008-05-19 2009-11-26 The Procter & Gamble Company Treatment of heart failure in women
EP2410859A4 (en) * 2009-03-27 2013-03-13 Agile Therapeutics Inc Transdermal delivery

Also Published As

Publication number Publication date
JP6316749B2 (en) 2018-04-25
MX353713B (en) 2018-01-24
US20160250226A1 (en) 2016-09-01
CA2854164A1 (en) 2013-05-10
KR20140088199A (en) 2014-07-09
EP2773333A1 (en) 2014-09-10
NZ624117A (en) 2016-02-26
ES2762460T3 (en) 2020-05-25
BR112014010670A2 (en) 2017-05-09
US20130116222A1 (en) 2013-05-09
ZA201402988B (en) 2015-11-25
HK1200317A1 (en) 2015-08-07
US9364487B2 (en) 2016-06-14
CN103957899A (en) 2014-07-30
EA026664B1 (en) 2017-05-31
HK1201152A1 (en) 2015-08-28
EP2773333B1 (en) 2019-10-02
US20180325916A1 (en) 2018-11-15
AU2012332254A1 (en) 2014-05-15
EA201400543A1 (en) 2014-09-30
JP2014532719A (en) 2014-12-08
MX2014005294A (en) 2014-09-22
CA2854164C (en) 2021-04-13
IL232258A0 (en) 2014-06-30
AU2012332254B2 (en) 2017-06-22
WO2013067346A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
IN2014DN03247A (en)
MX365818B (en) Natural combination hormone replacement formulations and therapies.
MX2014015898A (en) Natural combination hormone replacement formulations and therapies.
WO2010081032A3 (en) Steroidal compositions
PH12015501738A1 (en) Androgen receptor modulators and uses thereof
MX2013002975A (en) Estrogen receptor modulators and uses thereof.
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
BR112014031824A2 (en) transdermal hormone replacement therapies
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
GB201200062D0 (en) Estradiol oromucosal liquid compositions
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2015011132A (en) Polycyclic estrogen receptor modulators and uses thereof.
MX2012007933A (en) Topical transdermal dexmedetomidine compositions and methods of use thereof.
NZ609420A (en) Fulvestrant compositions and methods of use
MX2012000396A (en) Methods and compositions for use in cellular therapies.
CL2009001011A1 (en) Use of the compound 21-methoxy-17a-acetoxy-11ß- (4-n, n-dimethylaminophenyl) -19-norpregna-4,9-diene-3,20-dione (cdb-4124) to treat breast cancer; and use of the combination of cdb-4124 with an aromatase inhibitor.
MX367596B (en) Transdermal hormone replacement therapies.
MX2013004693A (en) Aripiprazole compositions and methods for its transdermal delivery.
NZ606730A (en) Methods for treating antipsychotic-induced weight gain
NZ714288A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
IN2014DN08598A (en)
MX2014002773A (en) Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases.
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
GB201022049D0 (en) Methods
MX2016004392A (en) Dual breaker system for reducing formation damage during fracturing.